Hägglund H - Search Results

1

Improved survival with ursodeoxycholic acid prophylaxis in allogeneic stem cell transplantation: long-term follow-up of a randomized study.

Ruutu T, Juvonen E, Remberger M, Remes K, Volin L, Mattsson J, Nihtinen A, Hägglund H, Ringdén O; Nordic Group for Blood and Marrow Transplantation. Ruutu T, et al. Among authors: hagglund h. Biol Blood Marrow Transplant. 2014 Jan;20(1):135-8. doi: 10.1016/j.bbmt.2013.10.014. Epub 2013 Oct 17. Biol Blood Marrow Transplant. 2014. PMID: 24141008 Free article. Clinical Trial.

2

Risk factors for acute graft-versus-host disease in 325 consecutive bone marrow recipients.

Hägglund H, Boström L, Ringdén O, Nilsson B, Remberger M. Hägglund H, et al. Transplant Proc. 1994 Jun;26(3):1821-2. Transplant Proc. 1994. PMID: 8030154 No abstract available.

3

Hepatitis C virus as a risk factor for the development of veno-occlusive disease of the liver.

Ljungman P, Hägglund H, Lönnqvist B, Sönnerborg A, Ringdén O. Ljungman P, et al. Among authors: hagglund h. Blood. 1994 Aug 15;84(4):1349-50. Blood. 1994. PMID: 8049452 No abstract available.

4

Does high-dose intravenous immune globulin treatment after bone marrow transplantation increase mortality in veno-occlusive disease of the liver?

Klaesson S, Ringdén O, Ljungman P, Aschan J, Hägglund H, Winiarski J. Klaesson S, et al. Among authors: hagglund h. Transplantation. 1995 Dec 15;60(11):1225-30. Transplantation. 1995. PMID: 8525515 Clinical Trial.

5

Risk factors for septicemia during aplastic period after allogeneic bone marrow transplantation.

Sparrelid E, Hägglund H, Remberger M, Ljungman P, Malmborg AS, Winiarski J, Andersson J, Ringdén O. Sparrelid E, et al. Among authors: hagglund h. Transplant Proc. 1995 Dec;27(6):3530. Transplant Proc. 1995. PMID: 8540085 No abstract available.

6

Bone marrow transplantation for chronic myelogenous leukemia using unrelated donors: the experience at Huddinge Hospital.

Aschan J, Ringdén O, Ljungman P, Hägglund H, Klaesson S, Dalianis T, Remberger M. Aschan J, et al. Among authors: hagglund h. Transplant Proc. 1995 Dec;27(6):3531-2. Transplant Proc. 1995. PMID: 8540086 Clinical Trial. No abstract available.

7

No beneficial effects, but severe side effects caused by recombinant human tissue plasminogen activator for treatment of hepatic veno-occlusive disease after allogeneic bone marrow transplantation.

Hägglund H, Ringdén O, Ljungman P, Winiarski J, Ericzon B, Tydén G. Hägglund H, et al. Transplant Proc. 1995 Dec;27(6):3535. Transplant Proc. 1995. PMID: 8540088 Clinical Trial. No abstract available.

8

Transplantation of peripheral blood progenitor cells from unrelated donors.

Ringdén O, Potter MN, Oakhill A, Cornish J, Hägglund H, Lönnqvist B, Shanwell A, Winiarski J, Pamphilon DH. Ringdén O, et al. Among authors: hagglund h. Bone Marrow Transplant. 1996 Mar;17 Suppl 2:S62-4. Bone Marrow Transplant. 1996. PMID: 8722340 Clinical Trial.

9

Risk factors for acute graft-versus-host disease in 291 consecutive HLA-identical bone marrow transplant recipients.

Hägglund H, Boström L, Remberger M, Ljungman P, Nilsson B, Ringdén O. Hägglund H, et al. Bone Marrow Transplant. 1995 Dec;16(6):747-53. Bone Marrow Transplant. 1995. PMID: 8750264

10

Transplantation with peripheral blood stem cells from unrelated donors without serious graft-versus-host disease.

Ringdén O, Lönnqvist B, Hägglund H, Ljungman P, Shanwell A, Lawlor E, Schmitz N. Ringdén O, et al. Among authors: hagglund h. Bone Marrow Transplant. 1995 Dec;16(6):856-7. Bone Marrow Transplant. 1995. PMID: 8750284 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

167 results

Search Page

Filters